| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 2.8K | 6.0% | 73.0% |
| Total Income | 2.9K | 6.5% | 73.6% |
| Expenditure | 2.5K | 3.8% | 86.0% |
| PBT | 343.35 | 30.9% | 15.7% |
| Net Profit | 301.15 | 45.3% | 16.5% |
| OPM | 19.39% | 1.89pp | 5.10pp |
| NPM | 10.40% | 2.78pp | 5.10pp |
| EPS | 14.82 | 45.3% | 16.6% |
Detailed report is being prepared.
Sustaining Q1's momentum: execution and new-bed ramp in focus
Healthcare operator trades 20% below consensus after a 78% revenue surge in Q1; Q2 will test whether growth sticks and operational expansion delivers without margin pressure.
The Setup
Narayana Hrudayalaya's Q1 FY27 delivered a statement: consolidated revenue surged 78% YoY to ₹26,836 Mn, with EBITDA at ₹5,052 Mn (+40% YoY), implying a 18.8% EBITDA margin — a level not seen in recent quarters. The company is executing on a playbook of organic capacity addition (₹460 Cr capex plan for FY27) and operational agreements that extend the footprint beyond owned beds. Analysts covering the stock expect this momentum to sustain: consensus FY27 earnings growth sits at 14.7%, anchored to a revenue CAGR of 12.6%. The question for Q2 is simple: does the company hold the margin level from Q1, and does new capacity added post-Sep (notably the KS-Narayana facility in Bengaluru, operational since Oct 5) begin to offset depreciation and startup costs?
~₹27,500–28,500 Cr
Moderate deceleration from Q1's 78% is normal; double-digit growth still in play (12–16% YoY)
18–19%
In line with Q1; new-bed startup costs and initial ops leverage will be key swing factors
Bed capacity utilization & ALOS
Standalone bed count, consolidation of operational agreements, and patient mix (oncology vs general) drive margin performance
GST demand ₹53.15 Lakh
Immaterial (~0.2 bps on revenue), but signals tax compliance scrutiny; no guidance yet on appeal timeline
What Strong vs Weak Looks Like
A strong Q2 posts revenue growth in the 14–18% YoY range (beating the consensus deceleration narrative), EBITDA margin sustained at 18.5% or above, and management commentary signalling a clear ramp timeline for the Bengaluru facility and the two new O&M agreements (Mission of Mercy Hospital, Assemblies of God). Bed-count additions and consolidation revenue would validate the capex roadmap. A weak Q2 shows revenue below 12% YoY growth or margins compressing below 17.5%, signalling either demand softness or higher-than-expected startup drag from new beds. Pricing pressure in core markets or patient-mix deterioration would raise red flags on FY27 margin sustainability.
On Track to Guidance?
The company has not published formal FY27 guidance, but investor presentations and management commentary point to a trajectory of steady expansion: ₹460 Cr capex, disciplined cost control, and operating-agreement partnerships to scale without balance-sheet strain. Q1 beat this narrative — a 40% EBITDA growth at margin expansion. Q2 is a test of whether Q1 was a one-off or the start of a normalized operating rhythm. Analysts polled by consensus assume it's sustainable; the stock's 20% discount to consensus target price suggests the market is pricing in a margin miss or execution stumble.
Since Last Quarter
The filing scan since Q1 shows operational progress and one tax headwind:
Oct 26
Board meeting announced for Oct 30 to approve Q2 results
Routine; result day locked
Oct 5
KS-Narayana Hospital (110 beds, Bengaluru) commences commercial operations
Positive: capacity addition live; ramp economics key to Q2 earnings
Oct 5
O&M agreement signed with Mission of Mercy Hospital (asset-light model)
Positive: diversifies footprint without large capex; consolidation timing TBD
Sep 28
GST demand notice issued: ₹53.15 Lakh penalty + interest
Negative but immaterial: tax compliance scrutiny; appeal likely
Sep 25
Trading window closed for insiders (Q2 blackout, effective Oct 1)
Routine; no insider signal
Sep 21
Corporate office relocation from Bommasandra to Whitefield
Routine operational housekeeping
The headline: three months of solid operational progress (new bed capacity, partnership expansion) offset by a single tax compliance issue. The GST penalty is immaterial (~0.2 bps of FY27 revenue), but it flags heightened regulatory scrutiny — something to monitor if more demands emerge post-result.
What to Watch on Result Day (Oct 30)
1 · EBITDA margin sustainability
The ₹5,052 Mn EBITDA in Q1 (18.8% margin) was a highlight. Q2 will show whether this holds or compresses under new-bed startup drag. Margin below 17.5% would signal execution risk on the FY27 capex roadmap.
2 · KS-Narayana ramp timeline
Management guidance on occupancy, ALOS, and contribution timeline for the Bengaluru facility (Oct 5 start) will shape near-term earnings expectations. Early occupancy data is critical.
3 · Consolidation of O&M agreements
Mission of Mercy and Assemblies of God partnerships are asset-light revenue catalysts. Q2 commentary on consolidation eligibility and timeline will clarify FY27–28 revenue contribution and validate investor thesis.
Narayana Hrudayalaya trades at a 20% discount to consensus fair value, having delivered a strong Q1. The market is pricing in either a margin miss or execution stumble in Q2–Q3 as the company scales beds and integrates partnerships. Q2 results on Oct 30 will test this skepticism: if margins hold and new-bed ramps stay on track, the 22–26% upside embedded in analyst targets becomes material. Watch EBITDA margin, the Bengaluru facility contribution, and any commentary on the O&M partnerships — these three will settle the debate on whether Q1 was a flash or the start of a normalized operating rhythm.